HHS proposes pulling 14 peptides off FDA's Category 2 list. What happens now?
The February 2026 announcement reopens the compounding question for BPC-157, GHK-Cu, CJC-1295, and 11 others. The path from proposal to pharmacy shelves runs through July's advisory committee.
On February 27, 2026, HHS Secretary RFK Jr. announced the proposed removal of 14 peptides from the FDA's Category 2 bulk drug substances list — the list of substances considered potentially unsafe for compounding under Section 503A and 503B. The 14 include BPC-157, GHK-Cu (injectable), CJC-1295, ipamorelin, MOTS-c, epitalon, thymosin alpha-1, KPV, and several others placed on the list in September 2023.
The announcement is the start of a process, not an end. Removal from Category 2 does not automatically place a substance on the Category 1 (compoundable) list. Each peptide must still undergo Pharmacy Compounding Advisory Committee (PCAC) review and receive a final FDA determination. The next procedural milestone is the July 2026 FDA Advisory Committee hearing.
What this means for patients
Nothing changes today. As of April 2026, all 14 peptides remain on Category 2 and cannot be legally compounded by US pharmacies. Research-peptide vendors continue selling them 'for research use only,' a designation the FDA has stated is void when paired with human-dosing information or therapeutic claims.
If the FDA ratifies the proposed removal after advisory-committee review, compounded access could return in late 2026 or 2027 depending on the ruling scope and any conditions imposed (labeling, purity testing, prescribing restrictions). Some peptides may return to full Category 1 status; others may be conditionally approved; some may remain Category 2 after review.
What's not addressed
The 2026 proposal does not cover the five Category 2 peptides excluded from the HHS removal list. It does not affect FDA-approved GLP-1 compounding rules (semaglutide and tirzepatide compounding was separately ended when their shortages resolved in 2024-2025). And it does not change the FDA's enforcement posture toward vendors selling peptides for unapproved human use regardless of Category 2 status.
Political context worth noting
The proposal is politically charged — RFK Jr.'s public statements on peptide availability predate his HHS appointment. Reporting from ProPublica and the Washington Post has covered the regulatory-science tensions around the decision. Our editorial position: regulatory policy should follow rigorous safety review, whatever the political cover story. The PCAC's July hearing is where that review will happen.
Sources